Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-07-04 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and changes in issued shares, which aligns with disclosures about transactions in own shares. There is no indication of it being a full financial report, earnings release, or management discussion. The document is not a report publication announcement or a certification letter but a regulatory disclosure of share repurchase activity. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS).
2023-07-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 June 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for an equity issuer listed on the Hong Kong Stock Exchange. It includes information on authorized and issued share capital, share options, confirmations by the company secretary, and compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital and share movements for the month ended 30 June 2023. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to share capital movements and confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a mere announcement but a formal regulatory return.
2023-07-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
Transaction in Own Shares Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2023. It details movements in authorized and issued share capital, share options, repurchases of shares, and other share-related activities. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share capital and share movements. It is a regulatory filing related to share capital movements and repurchases, not a financial report, earnings release, or management discussion. The document is about reporting share capital changes and repurchases, which fits the category of Transaction in Own Shares (POS). The length and detail confirm it is not a brief announcement but a formal regulatory return on share transactions by the company itself.
2023-07-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and changes in capital structure rather than financial results, management changes, or regulatory certifications. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, not merely an announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2023-07-03 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document is a list of directors and their roles and functions for World Houseware (Holdings) Limited, including details of board members and committee memberships. It does not contain financial data, earnings, or report content. It is an announcement related to board composition and governance structure. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on board roles, confirming it is not a full report or presentation.
2023-06-30 English
APPOINTMENT OF EXECUTIVE DIRECTORS, NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTORS
Board/Management Information Classification · 100% confidence The document is an announcement from the Board of World Houseware (Holdings) Limited regarding the appointment of new Executive Directors, a Non-executive Director, and Independent Non-executive Directors. It details the names, effective dates, and committee memberships of the appointees. There is no financial data, no report content, and no mention of financial results or regulatory filings beyond the announcement itself. The document is clearly about changes in the company's board of directors and senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 4893 characters, which is consistent with a detailed announcement rather than a full report or a brief notice. Hence, the classification is MANG with high confidence.
2023-06-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.